Novo Nordisk is raising the stakes in its push to outbid rival Pfizer for the development-stage drugmaker Metsera ...

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk lowered its full-year profit forecast on Wednesday in an early blow to the ...

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk on Wednesday reported third-quarter sales growth of 15%, beating forecasts in ...

Tokyo's benchmark Nikkei 225 index has dipped more than 4% and most other markets in Asia also sank after a retreat on Wall ...

Novo Nordisk is continuing to lose ground in the obesity and diabetes markets, with the Danish drugmaker saying it expected ...

COPENHAGEN (Reuters) -Wegovy-maker Novo Nordisk on Wednesday reported third-quarter sales growth of 11%, in line with ...

Denmark's Novo Nordisk, the maker of Ozempic and Wegovy obesity drugs, said on Wednesday it was lowering its 2025 outlook for the third time this year, after posting tepid third-quarter results.

Operating profit increased by 5% in Danish kroner and 10% at constant exchange rates (CER) to DKK 95.9 billion, impacted by one-off restructuring costs of around DKK 9 billion related to the ...

Stocks fell on Wall Street Tuesday, pulled down by losses in the same big tech companies that have been the main drivers of the market’s rally so far this year. The downturn pulled every major index ...